AgeX Therapeutics, Inc. | Business Contracts

Third Amendment to that certain Secured Convertible Facility Agreement, dated March 30, 2020, by and between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on March 15, 2023)

Reaffirmation Agreement, dated February 9, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 10, 2023)

Plan and Agreement of Merger, dated March 6, 2021, among Atlas Capital Partners Limited, GCLMS Acquisition Corporation, AgeX Therapeutics, Inc., and LifeMap Sciences, Inc (Filed With SEC on March 8, 2021)

Employment Agreement, by and between AgeX Therapeutics, Inc. and Andrea E. Park, dated May 15, 2020 (Filed With SEC on August 14, 2020)

Standard Sublease, dated for reference March 13, 2019, between AgeX Therapeutics, Inc. and InSite Vision, Inc (Filed With SEC on May 15, 2019)

Subordination Agreement, dated March 15, 2023, between AgeX Therapeutics, Inc., Serina Therapeutics, Inc. and the other investors signatory thereto (Filed With SEC on March 15, 2023)

Convertible Promissory Note, dated March 15, 2023, between AgeX Therapeutics, Inc. and Serina Therapeutics, Inc (Filed With SEC on March 15, 2023)

Convertible Note Purchase Agreement, dated March 15, 2023, between AgeX Therapeutics, Inc. and Serina Therapeutics, Inc (Filed With SEC on March 15, 2023)

Amended and Restated Security Agreement, dated March 13, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on March 15, 2023)

Secured Convertible Promissory Note dated March 13, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on March 15, 2023)

Amended and Restated Secured Convertible Promissory Note, dated February 9, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 10, 2023)

Amendment of 2017 Equity Inventive Plan (Filed With SEC on December 12, 2022)

Amendment No. 3 to Registration Rights Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)

Warrant Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)

Security Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)

Secured Note dated February 14, 2022, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)

Form of Warrant (Filed With SEC on February 15, 2022)

Amendment No. 2 to Loan Facility Agreement, dated November 8, 2021, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on November 9, 2021)

Amendment No. 2 to Registration Rights Agreement, dated February 10, 2021, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 11, 2021)

Amendment No. 1 to Loan Facility Agreement, dated February 10, 2021, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 11, 2021)

Second Amendment to Secured Convertible Facility Agreement, dated November 12, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on November 16, 2020)

First Amendment to Warrant Agreement, dated July 21, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited, including form of warrant (Filed With SEC on August 14, 2020)

First Amendment to Secured Convertible Facility Agreement, dated July 21, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on August 14, 2020)

Amendment No. 1 to Registration Rights Agreement, dated March 30, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on March 30, 2020)

Warrant Agreement, dated March 30, 2020, between AgeX Therapeutics, Inc. and Juvenescence Limited, including form of warrant (Filed With SEC on March 30, 2020)

Secured Convertible Facility Agreement, dated March 30, 2020, by and among AgeX Therapeutics, Inc., ReCyte Therapeutics, Inc., Reverse Bioengineering, Inc., and Juvenescence... (Filed With SEC on March 30, 2020)

Description of Securities (Filed With SEC on March 30, 2020)

Registration Rights Agreement, dated August 13, 2019, between AgeX Therapeutics, Inc. and Juvenescence, Ltd (Filed With SEC on August 14, 2019)

Warrant Agreement, dated August 13, 2019, between AgeX Therapeutics, Inc. and Juvenescence, Ltd (Filed With SEC on August 14, 2019)

Loan Facility Agreement, dated August 13, 2019, between AgeX Therapeutics, Inc. and Juvenescence, Ltd (Filed With SEC on August 14, 2019)

Warrant dated August 13, 2019 (Filed With SEC on August 14, 2019)

Compensation Agreement, dated March 1, 2019, between AgeX Therapeutics, Inc. and Russell L. Skibsted (Filed With SEC on May 15, 2019)

Warrant Agreement, dated February 28, 2018, including form of warrant (Filed With SEC on April 1, 2019)

AgeX Therapeutics, Inc. (33)